Skip to main content

Table 2 Arithmetic mean flea counts and percent efficacy relative to placebo at 24 h after treatment and weekly re-infestations with Ctenocephalides felis for dogs treated orally with Simparica Trio™, sarolaner-only, moxidectin-only or pyrantel-only tablets (Study 2)

From: Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs

Day after treatment

Treatment group

Flea count

% Efficacy

1

Placebo

70.1

Simparica Trio™

0*

100

Sarolaner

0*

100

Moxidectin

65.5

6.6

Pyrantel

66.6

5.0

7

Placebo

78.3

Simparica Trio™

0*

100

Sarolaner

1.9*

97.6

Moxidectin

66.4

15.2

Pyrantel

73.8

5.8

14

Placebo

65.8

Simparica Trio™

0*

100

Sarolaner

0*

100

Moxidectin

70.6

0

Pyrantel

76.8

0

21

Placebo

54.1

Simparica Trio™

0.1*

99.8

Sarolaner

0.4*

99.3

Moxidectin

64.8

0.0

Pyrantel

71.8a

0.0

28

Placebo

86.6

Simparica Trio™

0.3*

99.7

Sarolaner

0*

100

Moxidectin

78.9

8.9

Pyrantel

63.5b

26.7

35

Placebo

79.6

Simparica Trio™

0*

100

Sarolaner

0.4*

99.5

Moxidectin

79.4

0.3

Pyrantel

87.8

0

  1. *Flea counts are significantly lower than placebo; 7.78 ≤ t(35) ≤ 10.42, P < 0.0001
  2. aFlea count significantly higher than placebo; t(35) = − 3.00, P = 0.005
  3. bFlea count significantly lower than placebo; t(35) = 2.78, P = 0.0087